Cannabidiol prevention of cognitive deficits in a rat model for Alzheimer’s disease is associated with neuroinflammation
Progressive impairment of cognition is a key clinical feature of Alzheimer’s disease (AD), characterized by the accumulation of amyloid beta-protein (Aβ), tau hyperphosphorylation, neuroinflammation, and neuronal degeneration.Cannabidiol (CBD) is a safe, non-psychoactive phytocannabinoid that exhibits immunomodulatory activity in neurodegenerative disease, may ameliorate AD symptoms and slow cognitive decline.In this study, we aimed to examine whether chronic treatment with CBD can prevent cognitive and social deficits in a rat model of sporadic AD, and whether these changes are associated wit